The Feichter Group provides premium wealth management strategies to a select group of ultra-high-net-worth individuals, business owners, executives, and their families. Our clients are dynamic people who have built and led successful enterprises and created significant wealth in the process. The Feichter Group’s goal is to help create, implement, and maintain highly customized investment strategies to support its clients’ lifestyles, protect their assets, and empower them to leave enduring legacies.
The Feichter Group
William Blair Private Wealth Management
Across sectors, we have seen accelerated adoption of technology, business opportunity, and a deglobalized environment. Learn from our experts what this evolution means for a post-pandemic world.
Go to William Blair ThinkingAbout William Blair
William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
-
1935
Year William Blair was founded
-
1,900+
Employees worldwide
-
149 billion+
Client assets
-
89 Years
Independent and employee-owned
-
20+
Offices worldwide
-
~650
Companies under coverage
As of September 30, 2024
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
Thought Leadership
-
-
Asset Allocation: Your Biggest Investment Decision
Building a portfolio involves countless decisions. But none is more important than how you allocate your wealth across asset classes. This white paper describes the process of developing a customized asset-allocation strategy, achieving meaningful diversification across and within asset classes, and monitoring allocations and reviewing portfolios.
-
Our Latest News
-
-
Vigil Neuroscience, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Vigil Neuroscience, Inc. (VIGL $2.47), a clinical-stage biopharma focused on developing microglial-targeting therapeutics by leveraging genetic insights into degenerative disorders of the central nervous system (CNS).
-